Format

Send to

Choose Destination
Am J Respir Crit Care Med. 2018 May 1;197(9):1147-1156. doi: 10.1164/rccm.201710-1995OC.

Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial.

Author information

1
1 Department of Medicine, McGill University, Montreal, Quebec, Canada.
2
2 Regroupement de Soins Critiques Respiratoires, Réseau de Santé Respiratoire, Fonds de Recherche du Québec-Santé, Montréal, Québec, Canada.
3
3 School of Pharmacy, Northeastern University, Boston, Massachusetts; and.
4
4 Department of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts.

Abstract

RATIONALE:

Dexmedetomidine is associated with less delirium than benzodiazepines and better sleep architecture than either benzodiazepines or propofol; its effect on delirium and sleep when administered at night to patients requiring sedation remains unclear.

OBJECTIVES:

To determine if nocturnal dexmedetomidine prevents delirium and improves sleep in critically ill adults.

METHODS:

This two-center, double-blind, placebo-controlled trial randomized 100 delirium-free critically ill adults receiving sedatives to receive nocturnal (9:30 p.m. to 6:15 a.m.) intravenous dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg /kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h was reached) or placebo until ICU discharge. During study infusions, all sedatives were halved; opioids were unchanged. Delirium was assessed using the Intensive Care Delirium Screening Checklist every 12 hours throughout the ICU admission. Sleep was evaluated each morning by the Leeds Sleep Evaluation Questionnaire.

MEASUREMENTS AND MAIN RESULTS:

Nocturnal dexmedetomidine (vs. placebo) was associated with a greater proportion of patients who remained delirium-free during the ICU stay (dexmedetomidine [40 (80%) of 50 patients] vs. placebo [27 (54%) of 50 patients]; relative risk, 0.44; 95% confidence interval, 0.23-0.82; P = 0.006). The average Leeds Sleep Evaluation Questionnaire score was similar (mean difference, 0.02; 95% confidence interval, 0.42-1.92) between the 34 dexmedetomidine (average seven assessments per patient) and 30 placebo (six per patient) group patients able to provide one or more assessments. Incidence of hypotension, bradycardia, or both did not differ significantly between groups.

CONCLUSIONS:

Nocturnal administration of low-dose dexmedetomidine in critically ill adults reduces the incidence of delirium during the ICU stay; patient-reported sleep quality appears unchanged. Clinical trial registered with www.clinicaltrials.gov (NCT01791296).

KEYWORDS:

delirium; dexmedetomidine; intensive care; randomized controlled trial; sleep

PMID:
29498534
DOI:
10.1164/rccm.201710-1995OC

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center